The combination of chemotherapy and molecular targeted therapy could synergistically exert antitumor effects, holding an immense prospect of its application in treating GC.[5] Currently, the majority of targeted drugs for GC are anti‐human epidermal growth factor receptor 2 or anti‐epidermal growth factor receptor gene therapy drugs, and immunotherapy drugs.[6] However, positive response rates of these targeted agents for GC are relatively low, and only a very few patients can benefit from targeted therapy. The gene discussed is EGFR; the disease is gastric cancer.